Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Repeat Doses of SUSTOL in Adults
NCT05434663Phase 4Active, not recruiting
- Sponsor
- Heron Therapeutics, Inc.
- Start
- Jul 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of granisetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Heron Therapeutics, Inc.. Started Jul 2022; status: active, not recruiting.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05434663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05434663.